Macrocycle goes full Circle
A macrocycle-based therapy enters the clinic, as do projects targeting p53 interaction and IL-12.
Interim miss slows IO Biotech
An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.
A failed trial is a failed trial, says China’s regulator
The NMPA has refused to back PFS, plus subgroup OS analyses, in fruquintinib’s stomach cancer study.
A triple-negative breast cancer face-off
Duelling pivotal trials of anti-TROP2 ADCs should yield their first data imminently.
